Diabetes News and Research

Latest Diabetes News and Research

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

The Company's net loss for the quarter ended October 31, 2009 amounted to $2.5 million or ($0.01) per share, compared to $10.9 million or ($0.04) per share, for the quarter ended October 31, 2008.

29 Jan 2010

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes in this second edition to Prof. Robert J. Lefkowitz (1943, New York, United States), investigator in the Department of Medicine at Duke University (United States).

29 Jan 2010

Johns Hopkins University School of Nursing: Research news

Bridging a Cultural Healthcare Gap—Like other new immigrant groups, Korean Americans' health risks—diabetes, high blood pressure, and cancer—increase after arriving in the U.S. Unfortunately, too many also miss out on needed healthcare services until they are seriously, often chronically ill.

29 Jan 2010

Blood flowing with force protects against dangerous clogs in blood vessels

It is second nature for most of us that exercise protects against heart attack and stroke, but researchers have spent 30 years unraveling the biochemistry behind the idea. One answer first offered by researchers at the University of Rochester Medical Center is that athletic hearts push blood through arteries with greater force, which alone triggers reactions that protect against dangerous clogs in blood vessels.

29 Jan 2010

Diamyd Medical announces share capital and total number of shares as of January 29, 2010

As of January 29, 2010, the share capital in Diamyd Medical AB (publ.) is 14 330 494 SEK. The total number of votes is 4 160 187 and the total number of shares is 28 660 988, divided among 1 437 876 shares of series A (1 vote) and 27 223 112 shares of series B (1/10 vote).

29 Jan 2010

Hormones & Cancer: A new journal from The Endocrine Society

Today, The Endocrine Society unveiled its newest journal, Hormones & Cancer. This bi-monthly journal will include research articles covering all aspects of hormone action on cancer causation, progression, dependence, prevention, resistance and treatment.

29 Jan 2010

Targeted sequencing of exome can help identify potential disease-causing genes

Researchers from University of Miami Miller School of Medicine and Roche Applied Science have recently published a research study on human exome resequencing results from eight individuals that span across three generations of a family. The findings of this study showcased the value of targeted enrichment for family-based studies which allows researchers to quickly identify potential disease-causing genetic variants and will provide the data and information for further research to better understand disease and the impact across generations of a family.

29 Jan 2010

Diabetes vaccine: Diamyd Medical to file for market approval in 2011

In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.

29 Jan 2010

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

How to recognize heart attack symptoms in younger women

The risk for heart-related death is increasing in young adults ages 35 to 54, and the numbers are even more alarming for younger women. It is the number-one cause of death for both men and women in the United States, yet every year since 1984 more women have died of cardiovascular health problems than men, according to the American Heart Association.

29 Jan 2010

NHMRC awards Development Grant to speed up chronic wound treatment

A new treatment that could one day benefit burns victims, diabetes sufferers and the elderly - by fast tracking the healing of chronic wounds - has taken another step towards commercialization.

29 Jan 2010

Health benefits of aerobics can be greatly affected by what you eat after exercise

Many of the health benefits of aerobic exercise are due to the most recent exercise session (rather than weeks, months and even years of exercise training), and the nature of these benefits can be greatly affected by the food we eat afterwards, according to a study published in the Journal of Applied Physiology (http://jap.physiology.org).

29 Jan 2010

SCI indicates increased risk of declining kidney function in type 2 diabetics

In patients with type 2 diabetes, silent cerebral infarction (SCI)—small areas of brain damage caused by injury to small blood vessels—signals an increased risk of progressive kidney disease and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

29 Jan 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

Life Technologies collaborates with Ignite Institute to create genomic sequencing center

Life Technologies Corporation and the Ignite Institute for Individualized Health announced today a collaboration to create a ground-breaking genomic sequencing center at Ignite’s new facility in Northern Virginia.

28 Jan 2010

Tornier and LifeCell commence enrollment in Conexa Reconstructive Tissue Matrix clinical trial

Tornier, Inc., a global leader in extremities and sports medicine orthopaedics, and LifeCell™ Corporation, a KCI Company, announced today the first 13 patients have been enrolled in a multi-center clinical trial to document the clinical value of Conexa™ Reconstructive Tissue Matrix for the surgical repair of large rotator cuff tears. Conexa™ is a porcine-derived tissue matrix with both biologic and mechanical properties that are important to support the repair of injured or surgically reconstructed soft tissue. Launched by Tornier for orthopaedic applications in October of 2008, Conexa™ has been used successfully in approximately 1,500 patients.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Healthscreen Solutions announces fiscal year end 2009 financial results

Healthscreen Solutions Inc., Canada's premier provider of physician practice enhancement services and electronic medical record (EMR) software, today announced its record fiscal year end 2009 financial results.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Novella Clinical and OSI Pharmaceuticals expand existing clinical service agreement

Novella Clinical Inc. (formerly PharmaLinkFHI) and OSI Pharmaceuticals, Inc. announced today that the Companies will expand their existing clinical service agreement. Under the terms of the new agreement, effective February 1, 2010, Novella will provide clinical research and related services to OSI for a period of two years as OSI transitions its clinical operations to its new Ardsley, New York campus. Novella will assume use of some of OSI’s facilities in Boulder and employ members of OSI’s Boulder staff.

28 Jan 2010